Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + TPF followed by platinum-based chemoradiation in unresectable head and neck squamous cell carcinoma
2006-004189-14Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Feasibility of platinum-based chemoradiation regimens. Started Dec 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-004189-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004189-14.